Loading...
SUN-340 Prolactinoma Response to Bevacizumab Is Influenced by Tumor Progression Stage at the Beginning of Treatment
Anti-VEGF therapy is being implemented as second line drug for aggressive pituitary adenomas that do not respond to conventional treatments. Although it is approved for treatment of several cancers, many of them acquire resistance. In the present work, we evaluated Bevacizumab (BVZ) effect in an in...
Na minha lista:
| Udgivet i: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Endocrine Society
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553318/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-340 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|